A retrospective study on hormone replacement therapy after ovarian cancer surgery at our hospital

TL;DR

This study examines the use of hormone replacement therapy in ovarian cancer patients and finds a 14% cancer recurrence rate with few serious side effects.

Contribution

The study provides insights into HRT administration and outcomes in ovarian cancer patients in Japan.

Findings

14.3% of patients experienced cancer recurrence after HRT.

Only minor adverse reactions like skin eruptions were observed.

The study highlights the need for standardized HRT protocols in Japan.

Abstract

Hormone replacement therapy (HRT) is considered for ovarian cancer patients who develop menopausal symptoms, dyslipidemia, and osteoporosis due to iatrogenic menopause caused by surgery or anticancer drug treatment. However, there have been few reports on HRT administration methods and those that evaluate cancer recurrence and complications of HRT.

We examined the administration method, adverse reactions and cancer recurrence in 28 patients who received HRT after ovarian cancer surgery at our hospital.

All patients received estradiol monotherapy, and cancer recurrence was observed in four patients (14.3%); adverse reactions included skin eruption in two patients (7.1%), there were no other serious adverse reactions noted.

The method and duration of HRT administration and the timing of HRT discontinuation remain debated. Thus, a large-scale survey and standardization of HRT administration methods after ovarian cancer surgery in Japan are needed.